rosiglitazone has been researched along with calcitriol in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fujita, T; Fukumoto, S; Miyamoto, M; Okazaki, R; Takeuchi, Y; Tanaka, K; Toriumi, M | 1 |
| Benavides, S; Romo, A | 1 |
| Bruedigam, C; Chiba, H; Koedam, M; van der Eerden, BC; van Leeuwen, JP; Woeckel, VJ | 1 |
| Czekuć-Kryskiewicz, E; Karczmarewicz, E; Lorenc, RS | 1 |
2 review(s) available for rosiglitazone and calcitriol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Pathologies of calcium-phosphate homeostasis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Bone and Bones; Calcitriol; Calcium Phosphates; Disease Progression; Fibroblast Growth Factor-23; Homeostasis; Humans; Hyperphosphatemia; Kidney; Parathyroid Glands; Parathyroid Hormone; Renal Insufficiency, Chronic; Renin-Angiotensin System; Rosiglitazone; Thiazolidinediones; Up-Regulation; Vitamin D | 2012 |
5 other study(ies) available for rosiglitazone and calcitriol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro.
Topics: Acid Phosphatase; Adipocytes; Animals; Bone Marrow Cells; Bone Resorption; Calcitriol; Cell Differentiation; Cells, Cultured; Chromans; Hypoglycemic Agents; Interleukin-11; Isoenzymes; Mice; Mice, Inbred ICR; Osteoclasts; Parathyroid Hormone; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tartrate-Resistant Acid Phosphatase; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1999 |
Treatment options in insulin resistance obesity-related acanthosis nigricans.
Topics: Acanthosis Nigricans; Adolescent; Adult; Calcitriol; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Octreotide; Retinoids; Rosiglitazone; Thiazolidinediones; Vitamin D | 2008 |
1α,25-dihydroxyvitamin D3 and rosiglitazone synergistically enhance osteoblast-mediated mineralization.
Topics: Alkaline Phosphatase; Angiopoietin-Like Protein 4; Angiopoietins; Bone Density Conservation Agents; Calcification, Physiologic; Calcitriol; Cell Differentiation; Cell Line; Drug Synergism; Extracellular Matrix; Fatty Acid-Binding Proteins; Gene Expression Regulation, Enzymologic; Humans; Hypoglycemic Agents; Osteoblasts; PPAR alpha; PPAR gamma; PPAR-beta; Receptors, Calcitriol; Rosiglitazone; Signal Transduction; Steroid Hydroxylases; Thiazolidinediones; Vitamin D3 24-Hydroxylase | 2013 |